APA (7th ed.) Citation

TH, C., MF, T., SG, W., YN, L., HD, W., TH, T., . . . JY, S. (2026). The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer. Frontiers in oncology, 16, 1699471. https://doi.org/10.3389/fonc.2026.1699471

Chicago Style (17th ed.) Citation

TH, Chang, et al. "The STAT3-ZEB1 Axis Contributes to CCL2-mediated Resistance to Osimertinib in Lung Cancer." Frontiers in Oncology 16 (2026): 1699471. https://doi.org/10.3389/fonc.2026.1699471.

MLA (9th ed.) Citation

TH, Chang, et al. "The STAT3-ZEB1 Axis Contributes to CCL2-mediated Resistance to Osimertinib in Lung Cancer." Frontiers in Oncology, vol. 16, 2026, p. 1699471, https://doi.org/10.3389/fonc.2026.1699471.